### Learner Notification

**MED Learning Group**

**Histologic Remission as a Treatment Target in Ulcerative Colitis: Is it Ready for Prime Time?**

**Various Dates: April 17, 2023 – July 6, 2023**

**Online**

**Acknowledgement of Financial Commercial Support**

Lilly

**Acknowledgement of In-Kind Commercial Support**

No in-kind commercial support was received for this educational activity.

**Satisfactory Completion**

Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

**Joint Accreditation Statement**

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MED Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

**Nurses (ANCC) Credit Designation**

Amedco LLC designates this activity for a maximum of 1.00 ANCC contact hours.

###### Objectives - After Attending This Program You Should Be Able To

1. Distinguish histologic healing as a treatment target for patients with ulcerative colitis.
2. Assess data on the association between histologic remission in ulcerative colitis and patient outcomes.
3. Utilize appropriate tools for assessing histologic activity in patients.

**Disclosure of Conflict of Interest**

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-­‐6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

|  |  |  |
| --- | --- | --- |
| **First Name** | **Last Name** | **Commercial Interst: Relationship** |
| Russie | Allen | NA |
| Dave | Chatman | NA |
| Matthew | Frese | NA |
| Christina | Gallo | NA |
| Alexis | Klinger | NA |
| Marissa | Mays-Verman | NA |
| Alexandros | Polydorides | NA |
| David T. | Rubin | Takeda: Grant Support; Abbvie, Alimentiv Inc., Altuvio, Amgen, Arena Pharmaceuticals, Aslan Pharmaceuticals, Boehringer Ingelhein Ltd., Boston Consulting Group, Inc. (BCG), Bristol-Myers Squibb, Buhlmann Diagnostics Corp, Celgene Corp/Syneos, ClostraBio, Connect BioPharma, Datos Health Ltd, Ferring Pharms, EcoR1, Evinature Ltd, Genentech/Roche, Gilead Sciences, IBD RPM dba Chronicles Health, Image Analysis Group (IAG), Iterative Health, Janssen Pharmaceuticals, Kaleido Biosciences, Lilly, Menten AI, Pfizer, Prometheus Biosciences, Reistone Biopharma, Sangamo Therapeutics, Shanghai Pharma Biotherapeutics USA, Takeda, Target RWE, Techlaba Inc., Trellus Health: Consultant |
| Jo | Shultz | NA |
| Ryan | Ungaro | AbbVie, Bristol Myers Squibb, Janssen, Pfizer, Takeda: Advisory Board Member/Consultant; AbbVie, Boehringer Ingelhein, Eli Lilly, Pfizer: Research |
| Lauren | Welch | NA |

Questions? Email Certificate@AmedcoEmail.com